{"id":"W4389623269","doi":"10.1016/j.clml.2023.12.005","title":"Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital; Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Roche Canada","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Follicular lymphoma; Neutropenia; Lymphoma; Adverse effect; Febrile neutropenia; Gastroenterology; Tumor lysis syndrome; Refractory (planetary science); Rituximab; Cyclophosphamide; Oncology; Surgery; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001328695,0.0004358896,0.001051248,0.0001532074,0.0002337814,0.0008813101,0.0002915476,0.000382107,0.0009668012],"category_scores_gemma":[0.0008821082,0.0001475375,0.0006103762,0.0002342318,0.0003468217,0.0004632154,0.0001561029,0.001610098,0.000303891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005410036,"about_ca_system_score_gemma":0.0004830928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003654599,"about_ca_topic_score_gemma":0.00112445,"domain_scores_codex":[0.9997393,0.0001104206,0.00001533951,0.00003941048,0.0000369839,0.00005845798],"domain_scores_gemma":[0.9996283,0.00009847771,0.00009886211,0.00003134473,0.00002922849,0.0001137904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3099853,0.01133758,0.04595874,0.001293807,0.003915302,0.0006426129,0.0007175545,0.005227983,0.1320331,0.0007618893,0.01168718,0.4764389],"study_design_scores_gemma":[0.2621295,0.4234248,0.241499,0.0003339835,0.005275256,0.003698347,0.0004025705,0.007318409,0.02139072,0.001270333,0.03313244,0.00012469],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911759,0.006053114,0.0002954288,0.00039919,0.0000394744,0.0001391123,0.0004496313,0.0000320263,0.001416154],"genre_scores_gemma":[0.9955735,0.001896462,0.0003220236,0.0004683061,0.0000651506,0.0001223509,0.0009073984,0.00001459151,0.0006301687],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001328695,"threshold_uncertainty_score":0.007026851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03510957312794868,"score_gpt":0.3631146871045697,"score_spread":0.328005113976621,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}